Page 106«..1020..105106107108..120130..»

Category Archives: Global News Feed

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Posted: August 22, 2022 at 2:55 am

OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET.

View original post here:
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Posted in Global News Feed | Comments Off on Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

Posted: August 22, 2022 at 2:55 am

Basel, Switzerland, 22 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET.

See the original post:
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

Posted in Global News Feed | Comments Off on Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Posted: August 22, 2022 at 2:55 am

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA).

Link:
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Posted in Global News Feed | Comments Off on Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Posted: August 22, 2022 at 2:55 am

Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced the signing of an agreement with YA II PN, Ltd, an exempted company incorporated in the Cayman Islands with limited liability, a company of the group of companies managed by Yorkville Advisors Global LP, its investment manager ("Yorkville"), for a financing via the issuance of convertible notes of up to CHF 20 million, to be drawn in tranches.

Continued here:
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Posted in Global News Feed | Comments Off on Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Annual Financial Report

Posted: August 22, 2022 at 2:55 am

DXS INTERNATIONAL PLC

See original here:
Annual Financial Report

Posted in Global News Feed | Comments Off on Annual Financial Report

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Posted: August 14, 2022 at 2:33 am

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.

Read this article:
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Posted in Global News Feed | Comments Off on Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Posted: August 14, 2022 at 2:33 am

—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment

Excerpt from:
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Posted in Global News Feed | Comments Off on Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever

Posted: August 14, 2022 at 2:33 am

Acquisition will create a vertically integrated Colorado cannabis company, significantly accelerating Bespoke’s growth strategy

View original post here:
Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever

Posted in Global News Feed | Comments Off on Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever

Spectral Announces Second Quarter Results and Provides Corporate Update

Posted: August 14, 2022 at 2:33 am

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Go here to read the rest:
Spectral Announces Second Quarter Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on Spectral Announces Second Quarter Results and Provides Corporate Update

SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

Posted: August 14, 2022 at 2:33 am

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

Go here to see the original:
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

Posted in Global News Feed | Comments Off on SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders

Page 106«..1020..105106107108..120130..»